BioSpace News Archive

Zynex, Inc., an innovative medical technology company specializing in manufacturing and selling non-invasive medical devices for pain management, stroke rehabilitation, cardiac monitoring and neurological diagnostics, announced orders and an increased Adjusted EBITDA estimate for Q3 2021.

Otsuka Pharmaceutical Co., Ltd. (Otsuka) and H. Lundbeck A/S (Lundbeck) report that the U.S. Food and Drug Administration (FDA) has accepted a Supplemental New Drug Application (sNDA) for the treatment of schizophrenia in adolescents with Rexulti® (brexpiprazole) and has granted Otsuka and Lundbeck Priority Review.

Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) previously announced that its partner Escugen Biotechnology Co, Ltd. (“Escugen”) and Sorrento’s subsidiary Levena (Suzhou) Biopharma Co., Ltd. (“Levena”) had received an approval letter from the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) for its Application for Clinical Trial (Acceptance No. CXSL2101069) of Recombinant Humanized Anti-Trop2 Mab-SN38 Conjugate.

Izotropic announced today that it completed noteworthy Q3 2021 milestones as previously announced and is currently ahead of schedule on its Q4 objective to begin the fabrication of IzoView.

MYND Diagnostics Inc., is pleased to announce that the Company’s proprietary biomarker test technology will be a pivotal component of a proposed clinical trial seeking partial funds from a $15 million fund allocated by the Australian government.

Prenosis, Inc., a precision diagnostics company transforming clinical diagnosis with predictive intelligence, announced the expansion of an existing partnership with Roche Diagnostics that will total close to $6M to improve and expedite the clinical recognition of sepsis through advanced precision diagnostics.

Verona Pharma plc, a clinical-stage biopharmaceutical company focused on respiratory diseases, announces the presentation of Phase 2 data demonstrating the positive effect of a pressurized metered-dose inhaler formulation of ensifentrine in patients with moderate to severe chronic obstructive pulmonary disease at CHEST Annual Meeting 2021 taking place on October 17-20.

Hemogenyx Pharmaceuticals plc, the biopharmaceutical group developing new therapies and treatments for blood diseases, announces that it has signed a licence agreement with the global biopharmaceutical company Eli Lilly and Company.

Biodesix, Inc., a leading data-driven diagnostic solutions company, announced that multiple data presentations will occur at the 2021 annual CHEST virtual conference.

Quantori , LLC today announced the appointment of Steve Labkoff, MD, to the position of Global Head of Clinical and Healthcare Informatics